We appreciate your interest in SAMiRNA™.
Due to the recent changes in our business model, we will no longer be supplying SAMiRNA™ to individual labs without a research collaboration. If you'd like to inquire about a potential collaboration, please contact siRNAgen Therapeutics.

Overview

Throughout the world, SAMiRNA™ Custom Services combines our pre-clinical research and rich experiences of nucleic acid synthesis and developments to supply the highest quality of DNA oligos and siRNAs using our own unique nanoparticle-based gene delivery technologies. We have been continuously striving to develop new drugs by partnering with global pharmaceutical companies and researching together on the development of SAMiRNA™, the newest technology for the latest next-generation RNAi drugs. Furthermore, we always try our best to provide the best information and service with the most reasonable price to provide new opportunity for researchers undergoing studies on in vivo siRNA through SAMiRNA™ Custom Service.

SAMiRNA™ (Self-Assembled-Micelle-inhibitory-RNA)

SAMiRNA™ is a RNAi drug substance in the form of nanoparticle that uses an innovative new technology developed by our company which has overcome the limitation of traditional therapeutic siRNA technology to safely deliver the siRNA to the in vivo target cells efficiently. As the world's only siRNA prodrug, SAMiRNA™ is a revolutionary RNAi substance composed of a single molecule structure of a nanoparticle which maintains its stability even when it is injected to the bloodstream. It can be selectively delivered to the cancerous and diseased cells. As it enters the target cell, it is converted to siRNA and degrade the cancer-inducing RNA. Most of the siRNA therapeutic technologies currently undergoing clinical tests involve formulation or encapsulation step that uses liposome as the delivery vehicle to transport the synthesized siRNA into the tissue. However, at this time, not only it is difficult to control the loading efficiency of siRNA into the liposome, but as siRNA normally has low loading efficiency, the drug has to undergo complicated QC process for isolation and purification of the packaged siRNA for mass production. Furthermore, some reports state that some lipid components consisting the liposome have toxicity. Unlike this formulation, SAMiRNA™ has overcome the traditional liposome siRNA drugs by being prepared as a single entity in a fully automated synthesis line by self-assembling in an aqueous solution to be made into a stable nanoparticles without formulation. The anticancer effect of this product has been already tested through animal tests. Moreover, SAMiRNA™ has less toxicity than the conventional siRNA carriers, allowing our product to be more advantageous than the others as the new generation drug candidate.

Features and Benefits

• Advanced mechanism
  The world's only technology delivering the native siRNA/miRNA through the single molecule nanoparticle transporter substance
• No side effects
  A safe drug delivery system with no inherent immune and inflammatory responses
• Low toxicity
  Only ~ 100 mpk of NOAEL in mouse
• High selectively
  Preferential delivery to tumors and inflammatory tissues, suitable for solid tumors, fibrotic diseases
• Advanced mechanism
  Single step automated synthesis process without the need of additional formulation or complicated quality control tests